The combined utility of myeloperoxidase (MPO) and paraoxonase 1 (PON1) as two important HDL-associated enzymes in coronary artery disease: Which has a stronger predictive role?

• Published in: Atherosclerosis 2019-01, Vol.280, p.7-13
• Main Authors: Variji, Atena, Shokri, Yasaman, Fallahpour, Samane, Zargari, Mehryar, Bagheri, Babak, Abediankenari, Saeid, Alizadeh, Ahad, Mahrooz, Abdolkarim
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aryldialkylphosphatase - blood; Biomarker; Biomarkers - blood; Coronary Angiography; Coronary artery disease; Coronary Artery Disease - blood; Coronary Artery Disease - diagnosis; False Positive Reactions; Female; Humans; Male; Middle Aged; Myeloperoxidase; Odds Ratio; Paraoxonase; Peroxidase - blood; Predictive value; Predictive Value of Tests; Risk Assessment; Risk Factors; ROC Curve
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2018.11.004

Serum paraoxonase 1 (PON1) and myeloperoxidase (MPO) are HDL-associated enzymes that contribute significantly to the formation of dysfunctional HDL. The present study thus seeks to comparatively analyze the predictive role of PON1, MPO and the MPO/PON1 ratio and to also evaluate which one has a stronger predictive role in their combined utility as an MPO/PON1 ratio in coronary artery disease (CAD). PON1 activity and MPO concentrations were determined in patients with established CAD and those without significant CAD. Receiver operating characteristic (ROC) curves were drawn by plotting true positivity versus false positivity. The ROC curve analyses showed that PON1 (AUC = 61%, p = 0.003) and MPO/PON1 (AUC = 60%, p = 0.01) have a better diagnostic performance than MPO (AUC = 50%, p = 0.42) in detecting patients with CAD. PON1 and MPO/PON1 were found to have a significantly stronger discriminatory power for the age range ≥52 and